AR082223A1 - Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo - Google Patents
Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodoInfo
- Publication number
- AR082223A1 AR082223A1 ARP110102545A ARP110102545A AR082223A1 AR 082223 A1 AR082223 A1 AR 082223A1 AR P110102545 A ARP110102545 A AR P110102545A AR P110102545 A ARP110102545 A AR P110102545A AR 082223 A1 AR082223 A1 AR 082223A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugate
- hgh
- human
- region
- human growth
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 8
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 8
- 239000000854 Human Growth Hormone Substances 0.000 abstract 8
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulación líquida de un conjugado de hormona del crecimiento humano (hGH) de efecto prolongado, libre de albúmina, que puede garantizar la estabilidad del conjugado de hGH durante su almacenamiento por períodos prolongados. El conjugado de hormona del crecimiento humano incluye una hGH unida a la región Fc de una inmunoglobulina, y tiene una mayor estabilidad in vivo que la forma nativa. La formulación líquida de conjugado de hGH que incluye una solución amortiguadora de pH 5.0 ~ 6.0, un alcohol de azúcar, una sal y un tensioactivo no iónico, y está libre de suero humano y de otros factores riesgosos que potencialmente pueden contaminarse con virus. La formulación provee una estabilidad excelente durante el almacenamiento, y brinda un conjugado de hGH de efecto prolongado compuesto por un polipeptido de hGh y la región Fc de una inmunoglobulina que tiene más peso molecular y mayor durabilidad en vivo que la forma nativa.Reivindicación 18: La formulación líquida de conjugado de la hormona del crecimiento humano de efecto prolongado de la reivindicación 17, en donde la región Fc de una inmunoglobulina es una región Fc de la IgG4 humana aglucosilada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100067796A KR101337797B1 (ko) | 2010-07-14 | 2010-07-14 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082223A1 true AR082223A1 (es) | 2012-11-21 |
Family
ID=45469941
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110102545A AR082223A1 (es) | 2010-07-14 | 2011-07-14 | Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo |
ARP180100643A AR113034A2 (es) | 2010-07-14 | 2018-03-20 | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100643A AR113034A2 (es) | 2010-07-14 | 2018-03-20 | Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado |
Country Status (13)
Country | Link |
---|---|
US (1) | US9061072B2 (es) |
EP (1) | EP2593084B1 (es) |
JP (1) | JP5946448B2 (es) |
KR (1) | KR101337797B1 (es) |
AR (2) | AR082223A1 (es) |
AU (1) | AU2011277203B2 (es) |
BR (1) | BR112013000902A2 (es) |
CA (1) | CA2805228C (es) |
ES (1) | ES2673022T3 (es) |
IL (1) | IL224225B (es) |
RU (1) | RU2623026C2 (es) |
TW (1) | TWI459961B (es) |
WO (1) | WO2012008779A2 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE042585T2 (hu) | 2011-06-17 | 2019-07-29 | Hanmi Science Co Ltd | Oxintomodulint és immunglobulin-fragmentumot tartalmazó konjugátum és alkalmazása |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
US10064951B2 (en) * | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
EP2916819B1 (en) * | 2012-11-06 | 2019-07-10 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
JP2016511275A (ja) | 2013-03-11 | 2016-04-14 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン化合物 |
CN105229035A (zh) * | 2013-03-11 | 2016-01-06 | 诺和诺德保健股份有限公司 | 生长激素化合物 |
WO2015046974A1 (ko) * | 2013-09-27 | 2015-04-02 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 제제 |
EA201691795A1 (ru) * | 2014-03-31 | 2017-03-31 | Ханми Фарм. Ко., Лтд. | Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
US20180111974A1 (en) * | 2014-12-10 | 2018-04-26 | Opko Biologics Ltd. | Methods of producing long acting ctp-modified growth hormone polypeptides |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9375478B1 (en) * | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US11208452B2 (en) | 2015-06-02 | 2021-12-28 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
US10301428B2 (en) | 2015-09-11 | 2019-05-28 | Dow Global Technologies Llc | Polyalkoxy fatty compound |
KR20180051543A (ko) * | 2015-09-11 | 2018-05-16 | 다우 글로벌 테크놀로지스 엘엘씨 | 단백질 및 폴리알콕시 지방 화합물을 포함하는 조성물 |
CA2999297A1 (en) * | 2015-09-24 | 2017-03-30 | Biomarin Pharmaceutical Inc. | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
KR20170079409A (ko) * | 2015-12-30 | 2017-07-10 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
MA49339A (fr) | 2017-04-05 | 2020-02-12 | Novo Nordisk As | Conjugués insuline-fc à extension oligomère |
US20220378882A1 (en) * | 2019-10-30 | 2022-12-01 | Jcr Pharmaceuticals Co., Ltd. | Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
NZ255158A (en) | 1992-07-31 | 1997-09-22 | Genentech Inc | Human growth hormone; stable pharmaceutically acceptable aqueous formulation and means for preparing and storing it |
US5519253A (en) * | 1993-09-07 | 1996-05-21 | Delco Electronics Corp. | Coaxial switch module |
US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
JP3723857B2 (ja) * | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | ヒト成長ホルモン含有水性医薬組成物 |
JP4944324B2 (ja) * | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー, インコーポレイテッド | 免疫グロブリン融合タンパク質 |
GB2371227A (en) * | 2001-01-10 | 2002-07-24 | Grandis Biotech Gmbh | Crystallisation - resistant aqueous growth hormone formulations |
US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
KR100537260B1 (ko) | 2003-09-03 | 2005-12-19 | 한미약품 주식회사 | 인간 성장 호르몬의 안정화된 액상 제제용 조성물 |
EP1682584B1 (en) * | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
BRPI0418115A (pt) | 2003-12-23 | 2007-04-17 | Pharmacia Corp | formulação lìquida estável de hormÈnio de crescimento |
US8077437B2 (en) * | 2004-11-08 | 2011-12-13 | Enecsys Limited | Integrated circuits and power supplies |
KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
KR100739728B1 (ko) * | 2005-09-01 | 2007-07-13 | 삼성전자주식회사 | 화상형성시스템 및 화상 형성 방법 |
US8400775B2 (en) * | 2007-07-06 | 2013-03-19 | GM Global Technology Operations LLC | Capacitor with direct DC connection to substrate |
TWI388570B (zh) * | 2008-07-23 | 2013-03-11 | Hanmi Science Co Ltd | 包含具有三個官能端的非肽醯聚合物的多肽複合物 |
JP2012510468A (ja) | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
-
2010
- 2010-07-14 KR KR1020100067796A patent/KR101337797B1/ko active IP Right Grant
-
2011
- 2011-07-14 AU AU2011277203A patent/AU2011277203B2/en not_active Ceased
- 2011-07-14 EP EP11807064.8A patent/EP2593084B1/en not_active Not-in-force
- 2011-07-14 BR BR112013000902-0A patent/BR112013000902A2/pt not_active IP Right Cessation
- 2011-07-14 AR ARP110102545A patent/AR082223A1/es not_active Application Discontinuation
- 2011-07-14 US US13/809,783 patent/US9061072B2/en not_active Expired - Fee Related
- 2011-07-14 WO PCT/KR2011/005194 patent/WO2012008779A2/en active Application Filing
- 2011-07-14 TW TW100125060A patent/TWI459961B/zh not_active IP Right Cessation
- 2011-07-14 JP JP2013519600A patent/JP5946448B2/ja not_active Expired - Fee Related
- 2011-07-14 ES ES11807064.8T patent/ES2673022T3/es active Active
- 2011-07-14 RU RU2013106276A patent/RU2623026C2/ru not_active IP Right Cessation
- 2011-07-14 CA CA2805228A patent/CA2805228C/en not_active Expired - Fee Related
-
2013
- 2013-01-14 IL IL224225A patent/IL224225B/en active IP Right Grant
-
2018
- 2018-03-20 AR ARP180100643A patent/AR113034A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2012008779A3 (en) | 2012-05-24 |
ES2673022T3 (es) | 2018-06-19 |
RU2013106276A (ru) | 2014-08-20 |
TWI459961B (zh) | 2014-11-11 |
CN103068366A (zh) | 2013-04-24 |
JP2013531034A (ja) | 2013-08-01 |
CA2805228C (en) | 2019-05-07 |
AU2011277203A1 (en) | 2013-02-28 |
EP2593084B1 (en) | 2018-03-14 |
US20130115231A1 (en) | 2013-05-09 |
CA2805228A1 (en) | 2012-01-19 |
WO2012008779A2 (en) | 2012-01-19 |
JP5946448B2 (ja) | 2016-07-06 |
TW201215404A (en) | 2012-04-16 |
AU2011277203B2 (en) | 2015-11-12 |
RU2623026C2 (ru) | 2017-06-21 |
AR113034A2 (es) | 2020-01-22 |
EP2593084A2 (en) | 2013-05-22 |
IL224225B (en) | 2018-07-31 |
US9061072B2 (en) | 2015-06-23 |
EP2593084A4 (en) | 2014-11-05 |
KR20120007182A (ko) | 2012-01-20 |
BR112013000902A2 (pt) | 2020-08-25 |
KR101337797B1 (ko) | 2013-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR082223A1 (es) | Formulacion liquida de un conjugado de hormona del crecimiento humano de efecto prolongado, metodo | |
AR121939A2 (es) | Composición líquida de un conjugado derivado de oxintomodulina de larga duración y procedimiento para prepararla | |
MX369479B (es) | Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada. | |
MX2015001217A (es) | Formulacion liquida de insulina de accion prolongada y de peptido insulinotropico. | |
MX369201B (es) | Formulación líquida de un conjugado de insulina de acción prolongada. | |
AR063150A1 (es) | Formulaciones estables | |
PE20140795A1 (es) | Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada | |
EP2598660A4 (en) | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIODEGRADS DURING TRANSPORT AND STORAGE IN AMBIENT TEMPERATURES | |
EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
EA200970880A1 (ru) | Стабильные композиции на основе антител | |
EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
BR112013026883A2 (pt) | Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica | |
PE20140734A1 (es) | Composicion y formulacion que comprende iduronato-2-sulfatasa humano recombinante y metodo de preparacion de las mismas | |
HRP20221139T1 (hr) | Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r) | |
NZ609469A (en) | Improved high concentration anti-tnfα antibody liquid formulations | |
RU2017101667A (ru) | Фармацевтические композиции | |
MX2013004595A (es) | Formulaciones liquidas de un conjugado de alfa interferon de accion prolongada. | |
TW201129387A (en) | Liquid formulation for long-acting G-CSF conjugate | |
MX369511B (es) | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada. | |
AR097840A1 (es) | Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit | |
AR089231A1 (es) | Metodo de floculacion | |
PE20131034A1 (es) | El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional | |
AR090583A1 (es) | Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada | |
AR088048A1 (es) | Señuelos notch1 humanos | |
AR107276A1 (es) | Una formulación líquida de conjugado de hormona del crecimiento humana de acción prolongada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |